{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"\ud83e\ude78 Reengineering Coagulation: Bridging Factors, Bypassing Factor VIII, Transforming Hemophilia","description":"\ud83e\ude78 Can you replace factor VIII without actually replacing factor VIII? Emicizumab does something more ingenious: this bispecific antibody bridges factor IXa and factor X, functionally recreating a critical role of factor VIIIa. \ud83d\udd2c After screening ~40,000 candidates, researchers engineered a therapy that enables convenient subcutaneous prophylaxis and works with or without factor VIII inhibitors. \ud83d\udc89 \ud83c\udfc6 Recognized with the 2026 Lasker\u2013DeBakey Clinical Medical Research Award, it offers a powerful lesson: sometimes the best way to replace a missing protein is to reengineer its function. \ud83e\uddec ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/42898245\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/206277500"}